Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma

Clinical trial NCT06056895 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06056895
Sponsor: University of Washington
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8 Clinical Stage IV Merkel Cell Carcinoma AJCC v8 Merkel Cell Carcinoma

Start date: 2023-11-08
Primary completion: 2027-01-31
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.